Pyxis Oncology Q1 net loss $19.2M; cash $150.8M; ODD for PYX-201 in pancreatic cancer

Pyxis Oncology, Inc.

2023-Q1 EPS reported -$0.54

Net loss of $19.2M ($0.54 per share) vs $31.4M ($0.97) in Q1 2022; R&D expenses $11.9M, G&A $9.1M.
Cash, equivalents, restricted cash and short-term investments $150.8M, no debt; runway into 1H 2025.
FDA granted Orphan Drug Designation for PYX-201 in pancreatic cancer; Phase 1 trial dosing underway.
Phase 1 trial of PYX-106 dosing expected to begin Q2 2023; preliminary data from both trials late 2023 to early 2024.
One-time $8M payment to Pfizer in Q1 for FACT platform license expansion.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Pyxis Oncology, Inc. reported the quarter ended March 31, 2023 results: net income Net loss was $19.2 million, or $0.54 per common share, for the three months ended March 31, 2023, EPS $0.54 per common share.

Period: the quarter ended March 31, 2023
Net income: Net loss was $19.2 million, or $0.54 per common share, for the three months ended March 31, 2023
EPS: $0.54 per common share
Result: reported results

Exact text from the filing

Net loss was $19.2 million, or $0.54 per common share, for the three months ended March 31, 2023

View on SEC.gov

Browse all earnings releases →

Pyxis Oncology, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-020833

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.